Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

(Progress of Disclosed Matters) Notice Concerning Continuation of the Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Largescale Purchase etc. of Company Share Certificates etc. by Dalton etc.

TOKYO, October 10, 2025 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) (the "Company"), as announced in the September 30, 2025 press release "Notice Regarding Termination of Procedures Based on the Response Policy to Large-Scale Purchase of Company Share Certificates etc., Following the Withdrawal of the Statement of Intent by Dalton etc.", received on September 30, 2025 from Dalton etc. a letter stating that the statement of intent for large-scale purchase actions etc. ("Statement of Intent") was being withdrawn ("Letter of Withdrawal"), and the Large-scale Purchase etc. under the Statement of Intent was consequently withdrawn, as a result of which the Company has terminated procedures based on the "Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purchase etc. of Company Share Certificates etc. by Dalton etc." ("Response Policy") introduced by the Company on July 1, 2025, which included sending the Information List to request information disclosure from Dalton etc. ("Procedures").

Since the receipt of the Letter of Withdrawal, the Company carefully considered the status of the Response Policy which was to be effective, in principle, until the conclusion of the board of directors meeting that is first convened after the Company's annual general meeting of shareholders convened in June 2026. As the result, **in light of the course of dialogue between the Company and Dalton etc. thus far, the content of the Letter of Withdrawal, and the assertions of Dalton etc. published on the website of Dalton etc. and by some news media as of today, the Company concerns regarding the Large-scale Purchase etc. contemplated by Dalton etc. have yet to be eliminated, and there remains an undeniable possibility that if the Company responds to the receipt of the Letter of Withdrawal by terminating the Response Policy prior to the expiry of its effective period, Dalton etc. might purchase more Company Shares for the sole purpose of pursuing its own interests, including privatization of the Company through a MBO, which could result in a conflict of interest with general shareholders and could impair the Company's medium-to-long term corporate value and/or the common interests of**

shareholders. Accordingly the Company hereby announces that it has decided to continued the Response Policy at this point in time.

For the detail on the Company's Opinion on Dalton's Press Release and the reasons , please refer to the URL below.

https://ssl4.eir-parts.net/doc/4886/ir_material4/262368/00.pdf

End

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp